Tetanus Toxoid
Tetanus toxoid is a vaccine component prepared by formaldehyde inactivation of tetanus neurotoxin (TeNT) from Clostridium tetani, which when administered as part of immunization schedules (DTaP, Td, Tdap), stimulates production of specific neutralizing antibodies that prevent the neurotoxin from binding to nerve terminals and blocking inhibitory neurotransmitter release. It forms the basis of universal tetanus immunization programs and is included in combination vaccines for pediatric and adult immunization. Booster doses maintain protective antibody levels throughout life.
治療領域
作用機序
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Tetanus toxoid is a vaccine component prepared by formaldehyde inactivation of tetanus neurotoxin (TeNT) from Clostridium tetani, which when administered as part of immunization schedules (DTaP, Td, Tdap), stimulates production of specific neutralizing antibodies that prevent the neurotoxin from binding to nerve terminals and blocking inhibitory neurotransmitter release. It forms the basis of universal tetanus immunization programs and is included in combination vaccines for pediatric and adult immunization. Booster doses maintain protective antibody levels throughout life.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Tetanus Toxoid is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108875. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="tetanus-toxoid"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/tetanus-toxoid/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/tetanus-toxoid/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/tetanus-toxoid/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="tetanus-toxoid"></drugfyi-drug>